glp 1 drugs and muscle loss GLP-1 Medications Loss: The Hidden Risk to Strength and Injury Recovery The GLP-1 Agonists and Obesity:
Description
Models suggest societal upheaval from anti-obesity medicines but impacts are hard to predict.

Next up: glucagon-like peptide 1 receptor agonists, known colloquially (and identified here) as GLPs

Disproportionality analysis using reporting odds ratios (ROR)
For Women & Men

CMSs efforts to expand Medicare coverage of GLP-1s for obesity could provide substantial benefits to millions of Medicare beneficiaries, given the potential demand for these highly effective medicationsThere are potential drawbacks to the short-term program, however.

Support for weight management goals